This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, J. L. Articles by Sandler, H. M. Search for Related Content PubMed PubMed Citation Articles by Chan, J. L. Articles by Sandler, H. M. Social Bookmarking                            What's this?

Survival and Failure Patterns of High-Grade Gliomas After Three-Dimensional Conformal Radiotherapy

From the Departments of Radiation Oncology, Neurology, and Radiology, University of Michigan Medical Center, Ann Arbor, MI.

Address reprint requests to June Chan, MD, Department of Radiation Oncology, UH-B2C490, Box 0010, University of Michigan Medical Center, 1500 E. Medical Center Dr, Ann Arbor, MI 48109; email: chanj{at}umich.edu

PURPOSE: The goal of three-dimensional (3-D) conformal radiation is to increase the dose delivered to tumor while minimizing dose to surrounding normal brain. Previously it has been shown that even escalated doses of 70 to 80 Gy have failure patterns that are predominantly local. This article describes the failure patterns and survival seen with high-grade gliomas given 90 Gy using a 3-D conformal intensity-modulated radiation technique.

PATIENTS AND METHODS: From April 1996 to April 1999, 34 patients with supratentorial high-grade gliomas were treated to 90 Gy. For those that recurred, failure patterns were defined in terms of percentage of recurrent tumor located within the high-dose region. Recurrences with more than 95% of their volume within the high-dose region were considered central; those with 80% to 95%, 20% to 80%, and less than 20% were considered in-field, marginal, and distant, respectively.

RESULTS: The median age was 55 years, and median follow-up was 11.7 months. At time of analysis, 23 (67.6%) of 34 patients had developed radiographic evidence of recurrence. The patterns of failure were 18 (78%) of 23 central, three (13%) of 23 in-field, two (9%) of 23 marginal, and zero (0%) of 23 distant. The median survival was 11.7 months, with 1-year survival of 47.1% and 2-year survival of 12.9%. No significant treatment toxicities were observed.

CONCLUSION: Despite dose escalation to 90 Gy, the predominant failure pattern in high-grade gliomas remains local. This suggests that close margins used in highly conformal treatments do not increase the risk of marginal or distant recurrences. Our results indicate that intensification of local radiotherapy with dose escalation is feasible and deserves further evaluation for high-grade gliomas.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394. [Abstract] [Full Text] [PDF]

				K. J. Stelzer, J. G. Douglas, D. A. Mankoff, D. L. Silbergeld, K. A. Krohn, G. E. Laramore, and A. M. Spence Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme Neuro-oncol, February 1, 2008; 10(1): 88 - 92. [Abstract] [Full Text] [PDF]

				B. E. Lally, G. A. Geiger, S. Kridel, A. E. Arcury-Quandt, M. E. Robbins, N. D. Kock, K. Wheeler, P. Peddi, A. Georgakilas, G. D. Kao, et al. Identification and Biological Evaluation of a Novel and Potent Small Molecule Radiation Sensitizer via an Unbiased Screen of a Chemical Library Cancer Res., September 15, 2007; 67(18): 8791 - 8799. [Abstract] [Full Text] [PDF]

				Z. Jiang, N. Pore, G. J. Cerniglia, R. Mick, M.-M. Georgescu, E. J. Bernhard, S. M. Hahn, A. K. Gupta, and A. Maity Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir Cancer Res., May 1, 2007; 67(9): 4467 - 4473. [Abstract] [Full Text] [PDF]

				M. Brada, M. Pijls-Johannesma, and D. De Ruysscher Proton Therapy in Clinical Practice: Current Clinical Evidence J. Clin. Oncol., March 10, 2007; 25(8): 965 - 970. [Full Text] [PDF]

				S.J. Price, R. Jena, N.G. Burnet, P.J. Hutchinson, A.F. Dean, A. Pena, J.D. Pickard, T.A. Carpenter, and J.H. Gillard Improved Delineation of Glioma Margins and Regions of Infiltration with the Use of Diffusion Tensor Imaging: An Image-Guided Biopsy Study. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1969 - 1974. [Abstract] [Full Text] [PDF]

				J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, T. L. Chenevert, B. A. Moffat, T. D. Johnson, C. R. Meyer, S. K. Mukherji, D. J. Quint, S. S. Gebarski, X. Fan, C. I. Tsien, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma PNAS, November 15, 2005; 102(46): 16759 - 16764. [Abstract] [Full Text] [PDF]

				B. A. Cohen, E. A. Knopp, H. Rusinek, J. S. Babb, D. Zagzag, and O. Gonen Assessing Global Invasion of Newly Diagnosed Glial Tumors with Whole-Brain Proton MR Spectroscopy AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2170 - 2177. [Abstract] [Full Text] [PDF]

				D. Vordermark, S. M. Evans, S. M. Hahn, K. D. Judy, and C. J. Koch Significance of Hypoxia in Malignant Glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84 Clin. Cancer Res., May 15, 2005; 11(10): 3966 - 3968. [Full Text] [PDF]

				D. E. Hall, B. A. Moffat, J. Stojanovska, T. D. Johnson, Z. Li, D. A. Hamstra, A. Rehemtulla, T. L. Chenevert, J. Carter, D. Pietronigro, et al. Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker Clin. Cancer Res., December 1, 2004; 10(23): 7852 - 7859. [Abstract] [Full Text] [PDF]

				P. D. Brown, J. T. Wald, M. W. McDermott, G. S. Baumann, and T. F. Cloughesy Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. RadioGraphics, November 1, 2003; 23(6): 1591 - 1611. [Full Text] [PDF]

				M. Suzuki, K. Nakamatsu, S. Kanamori, M. Okumra, T. Uchiyama, F. Akai, and Y. Nishimura Feasibility Study of the Simultaneous Integrated Boost (SIB) Method for Malignant Gliomas Using Intensity-modulated Radiotherapy (IMRT) Jpn. J. Clin. Oncol., June 1, 2003; 33(6): 271 - 277. [Abstract] [Full Text] [PDF]

				M. A. LaCombe, J. L. Chan, H. M. Sandler, and B. A. Fraass Radiotherapy Dose Escalation in High-Grade Gliomas J. Clin. Oncol., August 1, 2002; 20(15): 3358 - 3359. [Full Text] [PDF]

				J. Knisely Conformal Radiotherapy for High-Grade Gliomas: How Much Is Too Much? J. Clin. Oncol., August 1, 2002; 20(15): 3357 - 3358. [Full Text] [PDF]